Medpace (NASDAQ:MEDP) is a global clinical research organization (CRO) that provides comprehensive drug and medical device development services to pharmaceutical, biotechnology and medical device companies. The company’s full-service model covers all phases of clinical research, from early-stage Phase I trials through late-stage Phase IV studies, enabling sponsors to streamline development timelines and reduce complexity. Medpace’s integrated approach encompasses therapeutic expertise across oncology, cardiology, metabolic disease, central nervous system disorders and infectious diseases, among other areas.
Key service offerings include clinical monitoring, project management, biostatistics, data management and medical writing, supported by specialized units such as central laboratory services, imaging core lab operations, pharmacology and safety sciences. Medpace also provides regulatory consulting to help clients navigate regional and global approval pathways, ensuring alignment with local health authority requirements and industry best practices. This breadth of services allows the company to oversee trial execution, data analysis and regulatory submissions within a unified framework.
With headquarters in Cincinnati, Ohio, Medpace maintains a significant international presence, operating in more than 40 countries across North America, Europe, Asia-Pacific, Latin America and Africa. Its network of strategically located offices and laboratories enables efficient patient recruitment and site management, access to diverse patient populations and streamlined logistics. The company’s global footprint supports collaborations with academic institutions, hospitals and research centers to foster innovation and enhance trial delivery.
Founded in 1992 by Dr. August J. Troendle, Medpace has grown from a modest clinical monitoring firm into a leading mid-sized CRO. Under Dr. Troendle’s leadership as chairman and chief executive officer, the company has emphasized scientific rigor, operational excellence and a client-focused culture. Medpace’s management team combines decades of clinical research experience with a commitment to quality and regulatory compliance, positioning the firm to support both emerging biotech innovators and established pharmaceutical sponsors.
